Table S1. Baseline Clinical, Functional, Laboratory, and Hemodynamic Characteristics of the Patients

Characteristics	Atorvastatin (n=112)	Placebo (n=108)	*P*
Age, ys	35±13	37±13	0.20
Gender, n (%)			
Female	79 (71)	65 (60)	0.11
Male	33 (29)	43(40)	
Weight, kg	54±12	57±11	0.17
Systolic blood pressure, mmHg	112±15	113±15	0.66
Diastolic blood pressure, mmHg	75±12	73±12	0.32
Heart rates, beats/minute	80±11.8	81±10.6	0.60
Cause of pulmonary hypertension (%)			
Idiopathic	30 (27)	34 (32)	0.44
Congenital heart disease	59 (53)	38 (35)	0.01
Atrialseptal defect	18	5	
Ventricular septal defect	22	22	
Patent ductusarteriosus	12	5	
other	7	6	
Connective-tissue disease	8 (7)	13 (12)	0.22
CTEPH	15 (13)	23 (21)	0.12

WHO functional class, n (%)			
II	70 (63)	71 (66)	0.62
III	42 (37)	37 (34)	
Six-minute walk distance, m	355±74	346±84	0.45
Borg dyspnea index	3 (2, 4)	3 (2, 4)	0.27
Mixed venous oxygen saturation, %	65±8	66±8	0.22
Total cholesterol, mmol/L	4.0±0.9	4.2±1.0	0.29
Low-density lipoprotein, mmol/L	2.3±0.7	2.3±0.8	0.77
Hemodynamic parameters			
Right atrial pressure, mmHg	9±6	10±6	0.21
Mean pulmonary arterial pressure, mmHg	69±19	66±20	0.32
Pulmonary capillary wedge pressure, mmHg	9±4	10±4	0.75
Cardiac output, L/min	3.8±1.4	4.1±1.7	0.11
Cardiac indexes, L/min/m^2	2.4±0.8	2.6±1	0.19
Pulmonary vascular resistance, dyn·sec·cm^{-5}	1633±745	1456±699	0.07
Concomitant medication, n (%)			
Digoxin	67 (60)	58 (54)	0.36
Diuretics	87 (78)	84 (78)	0.99
Warfarin	64 (57)	60 (56)	0.81

Values are mean±SD, median (Q1, Q3)or n (%)when appropriate.